Diploma PLC (LON:DPLM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Diploma PLC (LON:DPLM) have earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 6,626.25.

DPLM has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Diploma from GBX 6,400 to GBX 7,200 and gave the company a “buy” rating in a research note on Wednesday. Shore Capital Group reissued a “hold” rating on shares of Diploma in a research report on Wednesday, March 18th. Royal Bank Of Canada upped their price objective on Diploma from GBX 6,600 to GBX 7,300 and gave the company an “outperform” rating in a research report on Wednesday. Jefferies Financial Group reissued a “hold” rating and issued a GBX 5,700 target price on shares of Diploma in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Diploma from GBX 5,120 to GBX 5,760 and gave the stock a “neutral” rating in a research note on Friday, March 27th.

Diploma Stock Performance

Shares of DPLM stock opened at GBX 6,815 on Friday. The stock has a fifty day moving average price of GBX 6,369.17 and a 200 day moving average price of GBX 5,767.02. The company has a debt-to-equity ratio of 47.65, a quick ratio of 0.80 and a current ratio of 2.06. The stock has a market cap of £9.14 billion, a PE ratio of 49.64, a P/E/G ratio of 2.82 and a beta of 0.92. Diploma has a 1 year low of GBX 4,558 and a 1 year high of GBX 7,295.

Diploma (LON:DPLM) last announced its quarterly earnings results on Tuesday, May 19th. The company reported GBX 74.70 earnings per share for the quarter. The business had revenue of £851.10 million during the quarter. Diploma had a return on equity of 18.55% and a net margin of 9.42%. Sell-side analysts forecast that Diploma will post 163.7995512 earnings per share for the current fiscal year.

Diploma News Roundup

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Diploma raised growth guidance again after reporting strong first-half results, reinforcing confidence that underlying demand remains resilient and margins are holding up well. Diploma lifts growth guidance (again)
• Positive Sentiment: Broker support has improved: Deutsche Bank lifted its price target to GBX 7,200 and kept a buy rating, while Royal Bank of Canada raised its target to GBX 7,300 with an outperform rating and Berenberg increased its target to GBX 9,000 with a buy rating. Broker updates
• Neutral Sentiment: Jefferies reaffirmed a hold rating with a GBX 5,700 target, suggesting not all analysts see the upside as immediate, though the broader tone remains constructive. Broker updates
• Neutral Sentiment: Diploma’s reported quarterly results showed revenue of £851.1 million and EPS of GBX 74.70, adding evidence of steady operating performance, but the market focus is mainly on the upgraded outlook rather than the quarter alone. Earnings report

Insider Buying and Selling

In other Diploma news, insider Ian El-Mokadem purchased 500 shares of the business’s stock in a transaction on Friday, March 20th. The stock was bought at an average cost of GBX 5,820 per share, for a total transaction of £29,100. Insiders own 1.14% of the company’s stock.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.